Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

Inventiva, a clinical-stage biopharmaceutical company based in Daix, France, is poised to participate in two significant investor conferences in June 2025. The firm, which specializes in developing oral therapies aimed at treating metabolic dysfunction-associated steatohepatitis (MASH), has announced that CEO Frédéric Cren will present a corporate overview during a fireside chat at the Jefferies Global Healthcare Conference. This event is scheduled for June 4, 2025, at 10:30 AM ET in New York City. Investors and interested parties can access a live webcast of the presentation through the Investors section of Inventiva’s website. A replay of the session will be available for a period of six months thereafter.

Additionally, Inventiva’s management team is set to engage in the UBS Spring Biotech Conference on June 24, 2025, also located in New York City. This participation highlights the company’s ongoing commitment to raise awareness about its research and development initiatives, particularly regarding its lead candidate, lanifibranor. Lanifibranor is a novel pan-PPAR agonist currently undergoing evaluation in the pivotal Phase 3 NATiV3 clinical trial, aimed at treating adult patients suffering from MASH—a progressive chronic liver disease with significant unmet medical needs.

As a public company listed on both Euronext Paris and the NASDAQ under the ticker symbol IVA, Inventiva seeks to broaden its outreach and attract potential investors interested in innovative biopharmaceutical developments. The firm’s participation in these conferences underscores its strategic vision and dedication to addressing critical health challenges in the realm of metabolic diseases. For more information, interested parties can visit the company’s website.

As Inventiva prepares to present at the Jefferies Global Healthcare Conference and UBS Spring Biotech Conference in June 2025, investors should closely monitor developments pertaining to the company and its lead asset, lanifibranor. As a clinical-stage biopharmaceutical company focused on metabolic dysfunction-associated steatohepatitis (MASH), Inventiva operates in a niche with considerable unmet medical needs that could translate into significant market opportunities.

The participation of CEO Frédéric Cren in the fireside chat is a vital opportunity for investors and analysts to gain insights into the company's strategic vision, progress on the NATiV3 pivotal Phase 3 clinical trial, and broader corporate developments. Given the increasing prevalence of MASH and the minor competition in the therapeutic landscape, a successful trial could enhance Inventiva's position in the market significantly.

Investors should keep an eye on how Inventiva articulates its value proposition for lanifibranor during these conferences, especially in terms of data that may emerge from the NATiV3 trial, as positive clinical outcomes could lead to increased market recognition and valuation. Furthermore, the streaming format of the presentations allows for wider accessibility, possibly attracting new investors intrigued by Inventiva's innovative pipeline.

In light of these upcoming events, strategic positioning is advisable. Investors looking for growth potential should consider adding Inventiva to their portfolios, particularly if they are optimistic about outcomes from the NATiV3 trial. However, as with any clinical-stage biotech investment, potential investors should weigh the inherent risks against the reward of entering a therapeutics space with significant coverage gaps.

In summary, Inventiva's forthcoming presentations at renowned investor conferences represent an important junction for stakeholders eager to gauge its future trajectory within the biopharmaceutical landscape.